趋化因子CXCR7/CXCL11/CXCL12生物轴在狼疮肾炎患者外周血中表达研究

摘要
图/表
参考文献(27)
相关文章 (15)

全文: PDF (503 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨CXC型趋化因子受体7（CXCR7）与双配体CXC型趋化因子配体（CXCL）11、CXCL12在狼疮肾炎（LN）外周血中表达水平及意义。方法选取江苏省徐州市中心医院（以下简称“我院”）风湿免疫科2018年10月至2020年10月就诊的40例系统性红斑狼疮（SLE）患者为研究对象。SLE患者分为LN组（24例），非LN组（16例）。20名健康对照组为我院同期体检者。采用流式细胞术分别检测三组外周血中CD3+CXCR7+T淋巴细胞、CD19+ CXCR7+B淋巴细胞表达。采用酶联免疫吸附试验法检测各组血清中CXCL11、CXCL12浓度水平。结果 LN组外周血中CD3+CXCR7+T淋巴细胞、CD19+CXCR7+B淋巴细胞表达百分比及血清中CXCL11、CXCL12表达水平均高于非LN组和健康对照组，差异均有统计学意义（P ＜ 0.05）。非LN组CD3+CXCR7+T淋巴细胞、CD19+CXCR7+B淋巴细胞、CXCL11、CXCL12表达水平高于健康对照组，差异均有统计学意义（P ＜ 0.05）。LN患者外周血中CD19+CXCR7+淋巴细胞、CD3+CXCR7+淋巴细胞、CXCL11、CXCL12表达均与24 h尿蛋白定量呈正相关（P ＜ 0.001）。结论 LN患者发病与CXCR7、CXCL11、CXCL12高表达有关，提示CXCR7/CXCL11/CXCL12生物轴可能在狼疮肾炎的发病中起重要作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	祖蓓蓓1 马倩倩2 饶咏梅2 李美荣2 刘琳2 张丽3▲

Abstract：Objective To investigate the expression level and significance of CXC chemokine receptor 7 (CXCR7) and CXC-type chemokine ligand (CXCL) 11 and CXCL12 in peripheral blood of lupus nephritis (LN). Methods Forty patients with systemic lupus erythematosus (SLE) treated in the Department of Rheumatology, Xuzhou Central Hospital(“our hospital” for short) from October 2018 to October 2020 were selected as the study subjects. SLE patients were divided into the LN group (n 24 cases) and the non-LN group (16 cases). Twenty healthy subjects in the control group were examined in our hospital during the same period. Flow cytometry was used to detect the expression of CD3+CXCR7+T lymphocytes and CD19+CXCR7+B lymphocytes in peripheral blood of the three groups. The concentrations of CXCL11 and CXCL12 in serum were detected by enzyme-linked immunosorbent assay. Results The expression percentage of CD3+CXCR7+T lymphocyte and CD19+CXCR7+B lymphocyte in peripheral blood and the expression levels of CXCL11 and CXCL12 in serum of LN group were higher than those of non-LN group and healthy control group, the differences were statistically significant (P ＜ 0.05). The expression levels of CD3+CXCR7+T lymphocytes, CD19+CXCR7+B lymphocytes, CXCL11 and CXCL12 in the non-LN group were higher than those of healthy control group, the differences were statistically significant(P ＜ 0.05). The expression levels of CD19+CXCR7+ lymphocytes, CD3+CXCR7+ lymphocytes, CXCL11, and CXCL12 in peripheral blood of patients with LN were positively correlated with the quantification of 24 h urinary protein (P ＜ 0.001). Conclusion The high expression levels of CXCR7, CXCL11, and CXCL12 are related to the pathogenesis of LN patients. The CXCR7/CXCL11/CXCL12 may play an important role in the pathogenesis of LN.

Key words： Lupus nephritis CXC chemokine receptor 7 Cxc-type chemokine ligand 11 Cxc-type chemokine ligand 12

基金资助:江苏省卫生健康委科研课题（F201840）；
江苏省徐州市科技项目（KC18033）。

通讯作者: ▲通讯作者

作者简介: 祖蓓蓓（1977.12-），女，硕士，副主任医师，硕士生导师，现任职于江苏省徐州市中心医院风湿免疫科；研究方向：系统性红斑狼疮发病机制。

引用本文:

祖蓓蓓1 马倩倩2 饶咏梅2 李美荣2 刘琳2 张丽3▲. 趋化因子CXCR7/CXCL11/CXCL12生物轴在狼疮肾炎患者外周血中表达研究[J]. 中国医药导报, 2022, 19(17): 139-142.
ZU Beibei1 MA Qianqian2 RAO Yongmei2 LI Meirong2 LIU Lin2 ZHANG Li3▲. Expression of CXCR7, CXCL11 and CXCL12 biological axis in the peripheral blood of patients with lupus nephritis. 中国医药导报, 2022, 19(17): 139-142.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I17/139

[1] Arriens C，Wren JD，Munroe ME，et al. Systemic lupus erythematosus biomarkers： the challenging quest [J]. Rhe-umatology （Oxford），2017，56（suppl）：i32-i45.
[2] Aringer M，Petri M. New classification criteria for systemic lupus erythematosus [J]. Curr Opin Rheumatol，2020，32（6）：590-596.
[3] Laufer JM，Legler DF. Beyond migration-chemokines in lymphocyte priming，differentiation，and modulating effector functions [J]. Leukoc Biol，2018，104（2）：301-312.
[4] Lounsbury N. Advances in CXCR7 Modulators [J]. Pharmaceuticals （Basel），2020，13（2）：33-48.
[5] Nguyen HT，Reyes-Alcaraz A，Yong HJ，et al. CXCR7：a β-arrestin-biased receptor that potentiates cell migration and recruits β-arrestin2 exclusively through Gβγ subunits and GRK2 [J]. Cell Biosci，2020，10（1）：134-153.
[6] Tawalbeh SM，Marin W，Morgan GA，et al. Serum protein biomarkers for juvenile dermatomyositis： a pilot study[J]. BMC Rheumatol，2020，1（4）：52-67.
[7] Puchert M，Koch C，Zieger K，et al. Identification of CXCL11 as part of chemokine network controlling skeletal muscle development [J]. Cell Tissue Res，2021，384（2）：499-511.
[8] Elia G. MIG in psoriatic arthritis [J]. Clin Ter，2018，169（6）：e297-e302.
[9] Crescioli C，Corinaldesi C，Riccieri V，et al. Association of circulating CXCL10 and CXCL11 with systemic sclerosis [J]. Ann Rheum Dis，2018，77（12）：1845-1846.
[10] Watanabe K，Penfold ME，Matsuda A，et al. Pathogenic role of CXCR7 in rheumatoid arthritis [J]. Arthritis Rheum，2010，62（11）：3211-3220.
[11] Padern G，Duflos C，Ferreira R，et al. Identification of a Novel Serum Proteomic Signature for Primary Sj?觟gren’s Syndrome [J]. Front Immunol，2021，12（2）：1-12.
[12] Yang P，Tan J，Yuan Z，et al. Expression profile of cytokines and chemokines in osteoarthritis patients： Proinflammatory roles for CXCL8 and CXCL11 to chondrocytes [J]. Int Immunopharmacol，2016，40（11）：16-23.
[13] Bombardier C，Gladman DD，Urowitz MB，et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE [J]. Arthritis Rheum，1992，35（6）：630-640.
[14] Petri M，Orbai AM，Alarcón GS，et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus [J]. Arthritis Rheum，2012，64（8）：2677-2686.
[15] Vacchini A，Locati M，Borroni EM. Overview and potential unifying themes of the atypical chemokine receptor family [J]. J Leukoc Biol，2016，99（6）：883-892.
[16] Hughes CE，Nibbs RJB. A guide to chemokines and their receptors [J]. FEBS J，2018，285（16）：2944-2971.
[17] Laufer JM，Legler DF. Beyond migration-chemokines in lymphocyte priming，differentiation，and modulating effector functions [J]. Leukoc Biol，2018，104（2）：301-312.
[18] Ulvmar MH，Hub E，Rot A. Atypical chemokine receptors [J]. Exp Cell Res，2011，317（5）：556-568.
[19] Steen A，Larsen O，Thiele S，et al. Biased and g protein-independent signaling of chemokine receptors [J]. Front Immunol，2014，5（277）：1-7.
[20] Wang C，Chen W，Shen J. CXCR7 Targeting and Its Major Disease Relevance [J]. Front Pharmacol，2018，21（9）：641-652.
[21] Nibbs RJ，Graham GJ. Immune regulation by atypical chemokine receptors [J]. Nat Rev Immunol，2013，13（11）：815-829.
[22] Huynh C，Dingemanse J，Meyer Zu，et al. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions [J]. Pharmacol Res，2020，161（11）：1-11.
[23] Puchert M，Obst J，Koch C，et al. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7 [J]. Cytokine，2020，125：154809.
[24] Wedemeyer MJ，Mahn SA，Getschman AE，et al. The chemokine X-factor： Structure-function analysis of the CXC motif at CXCR4 and ACKR3 [J]. J Biol Chem，2020，295（40）：13927-13939.
[25] Koch C，Engele J. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked [J]. Mol Pharmacol，2020，98（5）：577-585.
[26] 祖蓓蓓，刘琳，饶咏梅，等.系统性红斑狼疮患者外周血中趋化因子基质细胞衍生因子-1α及其受体CXC趋化因子受体4的检测及其临床意义[J].中华风湿病学杂志，2013，17（12）：828-832.
[27] 祖蓓蓓，饶咏梅，李美荣，等.狼疮肾炎患者外周血中趋化因子受体CXCR4及其配体SDF-1α的表达研究[J].临床与实验医学杂志，2013，13（23）：1884-1887.